Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · March 22, 2018

Durvalumab as Third-Line or Later Treatment for Advanced Non–Small Cell Lung Cancer

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Durvalumab as Third-Line or Later Treatment for Advanced Non-Small-Cell Lung Cancer (ATLANTIC): An Open-Label, Single-Arm, Phase 2 Study
Lancet Oncol 2018 Mar 12;[EPub Ahead of Print], MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, J Corral Jaime, JE Gray, J Powderly, C Chouaid, P Bidoli, P Wheatley-Price, K Park, RA Soo, Y Huang, C Wadsworth, PA Dennis, NA Rizvi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading